US-based Lannett has signed an agreement with Symplmed Pharmaceuticals to be the exclusive distributor in the US of an authorized generic version of ACEON (perindopril erbumine tablets) in 2mg, 4mg and 8mg dosage strengths.
ACEON is an angiotensin converting enzyme (ACE) inhibitor approved for the treatment of patients with high blood pressure (hypertension) and reduce the risk of heart attack in patients with stable coronary artery disease.
According to IMS, annual total sales of Perindopril Erbumine tablets, 2mg, 4mg and 8mg, at Average Wholesale Price (AWP) were about $3.5m.
Separately, Symplmed had completed ownership of perindopril franchise with acquisition of ACEON.
According to Symplmed, ACEON is its first marketed product and is available through its proprietary web portal, DyrctAxess, as part of a comprehensive hypertension-management offering.
Symplmed anticipates adding to its perindopril franchise with FDA approval of its investigational drug Prestalia, a single-pill, fixed-dose combination (FDC) of perindopril arginine and amlodipine besylate.
If approved by the FDA, this will be the first FDC of these two important medicines for the treatment of hypertension in the US.
Symplmed president and CEO Erik Emerson said the ACEON acquisition is an important milestone for the company as it continues to build its commercial presence in the US.
"We look forward to supporting ACEON and its loyal patients while continuing to grow our product portfolio through the perindopril program and industry partnerships," Emerson said.
Lannett develops, manufactures, packages, markets and distributes generic pharmaceutical products.